1-[4-[5-fluoro-6-(2H-pyrazolo[3,4-b]pyridin-3-yl)-2-pyridinyl]-6-methylpiperazin-2-yl]cyclobutan-1-ol
C20H23FN6O — CID 67949838
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[4-[5-fluoro-6-(2H-pyrazolo[3,4-b]pyridin-3-yl)-2-pyridinyl]-6-methylpiperazin-2-yl]cyclobutan-1-ol
1-[4-[5-fluoro-6-(2H-pyrazolo[3,4-b]pyridin-3-yl)-2-pyridinyl]-6-methylpiperazin-2-yl]cyclobutan-1-ol (PubChem CID 67949838) has the molecular formula C20H23FN6O and a molecular weight of 382.44 g/mol. Its IUPAC name is 1-[4-[5-fluoro-6-(2H-pyrazolo[3,4-b]pyridin-3-yl)-2-pyridinyl]-6-methylpiperazin-2-yl]cyclobutan-1-ol.
Molecular Properties
| Compound Name | 1-[4-[5-fluoro-6-(2H-pyrazolo[3,4-b]pyridin-3-yl)-2-pyridinyl]-6-methylpiperazin-2-yl]cyclobutan-1-ol |
|---|---|
| PubChem CID | 67949838 |
| Molecular Formula | C20H23FN6O |
| Molecular Weight | 382.44 g/mol |
| Exact Mass | 382.19 |
| IUPAC Name | 1-[4-[5-fluoro-6-(2H-pyrazolo[3,4-b]pyridin-3-yl)-2-pyridinyl]-6-methylpiperazin-2-yl]cyclobutan-1-ol |
| SMILES | CC1CN(c2ccc(F)c(-c3[nH]nc4ncccc34)n2)CC(C2(O)CCC2)N1 |
| InChI | InChI=1S/C20H23FN6O/c1-12-10-27(11-15(23-12)20(28)7-3-8-20)16-6-5-14(21)18(24-16)17-13-4-2-9-22-19(13)26-25-17/h2,4-6,9,12,15,23,28H,3,7-8,10-11H2,1H3,(H,22,25,26) |
| InChIKey | AQANWUTVYXBBFD-UHFFFAOYSA-N |
| XLogP | 2.24 |
| TPSA | 89.96 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 382.44 |
| LogP ≤ 5 | 2.24 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 67949838 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.